 (Roberts & 
4/15 (26%) grade 1, 5/18 (28%) grade 2 and 3/5 (60%) grade 3 tumours. There was no clear relationship to tumour stage, lymphocytic infiltration or stromal content of the tumours. Clinical review one year after the 2 year period of tumour collection showed that 6/9 (66%) of patients with tumours with reduced levels of transcript had died or had disease which was not controllable by local resection and 3/9 (33%) had developed tumour re-occurrences. In comparison, in the group with normal levels of expression of TGFPi1, 3/18 (17%) had disease which was not controllable by local means, 9/18 (50%) had tumour re-occurrence and 6/18 (33%) had no evidence of disease. The association of reduced expression of TGF%1 and advanced disease was statistically significant P<0.02 (Fisher's test) . Although the sample size is small, we suggest that the loss of expression of TGFP1 may be a potential marker of progressive disease or prognosis in transitional cell carcinoma and warrants further study.
The TGFPI group of peptide regulatory factors is a large expanding family of multi-functional genes displaying marked homology and evolutionary conservation (Roberts & Sporn, 1990) . TGFP is secreted in a latent form which is unable to bind to its receptor (Wakefield et al., 1987) . Activa- tion of this latent TGFP may be achieved in several ways including transient acidification, alkalinisation or chaotropic agents (Kryceve-Martinerie et al., 1985) .
The action of TGFP is mediated through binding to specific cell surface receptors. Almost all cells, regardless of origin, bind TGFP (Roberts & Sporn, 1990) . Three distinct classes of receptor with various affinities for TGFP1 and TGFPI2 have been described (Cheifetz et al., 1987) and it has been suggested that the cell specific effects of the individual forms of TGFP may be regulated by differences in the levels of receptors of different affinities present on those cells (Cheifetz et al., 1990) .
The pleiotropic effects of the TGFPi family have been extensively documented (for recent reviews see Moses et al., 1990 ; Roberts & Sporn, 1990) . The role of TGFPI in cell transformation is unclear. Most normal epithelial cells in tissue culture are growth inhibited by TGFP (Moses et al., 1985; Masui et al., 1986; Jetten et al., 1986; Kurokowa et al., 1987) . In contrast many carcinoma cells show reduced inhibition by TGFPI (Wakefield et al., 1987; Lechner et al., 1983; McMahon et al., 1986 ) and many transformed cell lines secrete increased amounts of TGFPI (Derynck et al., 1987; Jakowlew et al., 1988; Niitsu et al., 1988) which is reflected in an increase in the steady-state levels of TGFPI mRNA in these cell lines and in tumours. Such increased TGFPI production could contribute to tumour development and progression in multiple ways via paracrine effects on neovascularisation, extracellular matrix formation, chemotaxis and immunosuppression (Derynck et al., 1987; Wakefield et al., 1987) .
There have been few studies of TGFP production by human tumours. Raised levels of TGFP mRNA were reported in breast and renal tumours (Coombes et al., 1990; Gomella et al., 1989) . Similarly, TGFP1 RNA was detected in all glial tumour cells in a spectrum of cerebral malignancies (Mapstone et al., 1991) . TGFP secretion and growth response of urothelial cells has not been studied in detail. The only report on bladder epithelial cells to date showed that foetal urothelial cells but not transformed urothelial cells responded to exogenous TGFP1 by a decrease in plasminogen activator activity secondary to increased transcription of PAI-I activity (Hiti et al., 1990) .
Transitional cell carcinoma is the fourth most common cancer in males in the United Kingdom and the incidence is rising in both men and women (31% between 1971 (31% between and 1984 (31% between , OPCS, 1971 (31% between -1984 . Studies of the natural history of transitional cell carcinoma have identified an aggressive subset of tumours (Pryor, 1973 In these cases, urothelium from at least four biopsies from the same patient was pooled and processed together. Tissues were placed immediately at -70°C. The tissues used are shown in Table I . Tumours were graded according to W.H.O. recommendations (1973) and staged using the TNM system (UICC, 1978) .
Cells and cell culture
The cell lines used were EJ (Evans et al., 1977) , VM-CUB-2 (Williams, 1980) , SCaBER (O'Toole et al., 1976) , SD (Paulie et al., 1983) and SW1710 (Kyriazis et al., 1984) the fragments separated in 0.8% agarose gels. Gels were stained with ethidium bromide and photographed prior to capillary transfer (Southern, 1975) Fort et al., 1985) . Probes were labelled by random priming (Feinberg & Vogelstein, 1983 ) and used at 106 c.p.m. ml-' of hybridisation fluid. Levels of TGFPI2 expression were more varied. The level of expression of the three expected transcripts of 4.1 kb, 5.1 kb and 6.5 kb differed within the same bladder tumour cell line (Figure lb) . Expression of the 5.1 kb and 6.5 kb transcripts was greater than that of the 4.1 kb transcript. Total expression of TGFP2 RNA also varied markedly between cell lines.
All cell lines expressed two of the three expected transcripts of 6.5 kb and 5.1 kb respectively. VM-CUB-2 appeared to express higher levels of the 6.5 kb than the 5.1 kb transcript (Figure lb ) but all other lines expressed more of the 5.1 kb than the 6.5 kb transcript. This can be seen clearly for SWI710 in Figure lb Three tumour re-occurrences (we have used this term for subsequent tumours or 'recurrences' in the same patient, since the relationship between initial and subsequent tumours is unclear) were subsequently analysed. In two of these, the level of expression of TGFPI was the same as that detected in the initial sample. In the third, expression was reduced in the initial biopsy and normal in the second.
Of the ten matched field biopsies, four showed similar levels of expression of TGFP to the tumour from the same bladder. These were comparable to levels detected in normal urothelium. In three cases, transcript levels were reduced in the tumour and not the field biopsy. In one patient, levels were reduced in the field biopsy but not the tumour, in one patient levels were reduced in both field and tumour biopsies and in one patient transcript levels were raised in the tumour but normal in the field biopsy. Of the three unmatched field biopsies, one showed raised levels of transcript. In addition, two biopsies of follicular cystitis (both from patients in whom transitional cell carcinomas had been resected in the past) were assessed. One of these showed reduced levels of transcript. Only one of the samples of macroscopically 'normal' urothelium showed altered levels of transcript. This sample was obtained from a patient in whom no re-occurrences were detected at check cystoscopy. has been reported (Seyedin et al., 1985; Cheifetz et al., 1987; Assoian et al., 1983; Derynck et al., 1988; Wrann et al., 1987; Ikeda et al., 1987) . However, results obtained using cultured cells must be interpreted with caution. In this study, the cells were harvested at semi-confluence from media containing serum. Cell density in culture has been shown to affect response to exogenous growth factors including TGFP (Ke et al., 1990) The role of TGFPI1 in transformation remains unclear although the ability of transformed cells to respond to TGF,B1 is frequently altered (Lechner et al., 1983; McMahon et al., 1986; Shipley et al., 1986; Wakefield et al., 1987) . A number of studies suggest that altered expression of TGFP1 may play a part in transformation (Derynck et al., 1987; Jokowlew et al., 1988; Niitsu et al., 1988) . Increased levels of TGFPIB mRNA in tumours compared to adjacent tissues has been reported in a number of tumours (Derynck et al., 1987) , including breast and renal cell carcinoma (Coombes et al., 1990; Gomella et al., 1989) . It has been suggested that in- (Mizukami et al., 1990) . In these breast tumours, it was observed that tumours expressing TGFPI1
were associated with a better prognosis over 2 years. Thus, a reduction in TGFP expression may be common to both aggressive breast and bladder tumours. A number of other molecular changes have been described in both tumour types. These include amplification and overexpression of ERBB2 (Coombs et al., 1989 Slamon et al., 1987 Slamon et al., , 1989 , amplification at 1 1q13 involving INT2, HST and BCL1 Adnane et al., 1989) , and loss of heterozygosity of the RB gene Varley et al., 1989) .
The association of reduced expression of TGFPi1 mRNA and poor prognosis is in keeping with the known growth inhibitory activity of TGFP1 on normal epithelial cells. Loss of expression of TGFP1 might result in reduction of extracellular matrix formation, increased pericellular proteolysis and removal of the negative effect on proliferation (Sporn & Roberts, 1990) . Further studies are now required to investigate the relationship of TGFPi1 transcript levels to levels of the mature active gene product in bladder tumours. Although only a relatively small number of tumours have been examined, there appears to be a relationship between reduced levels of expression of TGFPI1 transcript and disease progression. From the information obtained in this study, the presumed loss of the inhibitory activity of TGFP1 in transitional cell carcinoma may be a late event in bladder carcinogenesis. However, this does not preclude its utility as a clinical marker of progression or prognosis.
